Dacomitinib, an emerging H ER-targe ted therapy for non-small cell lung cancer

Journal of Thoracic Disease

Volumn 4, Issue 6, 2012, Pages 639-642

  Carpenter, Richard L ^a   Lo, Hui Wen ^a,b  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DUKE CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANERTINIB; DACOMITINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; NERATINIB;

ACNE; ADVANCED CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER MORTALITY; CANCER RESISTANCE; COUGHING; DIARRHEA; DRUG DEVELOPMENT; DRUG EFFICACY; DRUG ERUPTION; DRUG HALF LIFE; DRUG PROTEIN BINDING; DRUG SAFETY; DYSPNEA; FATIGUE; GAIN OF FUNCTION MUTATION; HUMAN; LUNG NON SMALL CELL CANCER; MAXIMUM TOLERATED DOSE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POINT MUTATION; PROTEIN DOMAIN; REVIEW; THORAX PAIN; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR XENOGRAFT;

EID: 84873662890     PISSN: 20721439     EISSN: 20776624     Source Type: Journal    
DOI: 10.3978/j.issn.2072-1439.2012.10.09     Document Type: Review

References (29)

1. Ettinger DS, Akerley W, Bepler G., et al. Non-small cell lung cancer. J Natl Compr Cane Netw 2010; 8: 740-801.
2. Woodburn JR. The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol Tner 1999; 82:241-S0.
3. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350: 2129-39.
4. Paez JG, Janne PA, Lee J.C., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304: 1497-500.
5. Pao W, Miller V, Zakowski M., et al. EGF receptor gene mutations are common in lung cancers from "never smokers," and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 2004; 101: 13306-11.
6. Nguyen KS, Kobayashi S, Costa DB Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway. Clin Lung Cancer 2009; 10: 281-9.
7. Kobayashi S, Boggon TJ, Dayaram T, et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005; 352: 786-92.
8. Pao W, Miller VA, Politi K.A., et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005; 2:e73.
9. Engelman JA, Zejnullahu K, Gale C.M., et al PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib. Cancer Res 2007; 67: 11924-32.
10. Gonzales AJ, Hook KE, Althaus I.W., et al. Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor. Mol Cancer Ther 2008; 7: 1880-9.
11. Kwak EL, Sordella R, Bell D.W., et al. Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc Natl Acad Sci U S A 2005; 102: 7665-70.
12. Garuti L, Roberti M, Bottegoni G. Irreversible protein kinase inhibitors. Curr Med Chem 2011; 18: 2981-94.
13. Singh J, Petter RC, Baillie T.A., et al. The resurgence of covalent drugs. Nat Rev Drug Discov 2011; 10: 307-17.
14. Jänne P.A., Boss DS, Camidge D.R., et al. Phase I dose-escalation study of the pan-HER inhibitor, PF299804, in patients with advanced malignant solid tumors. Clin Cancer Res 2011; 17: 1131-9.
15. Takahashi T, Boku N, Murakami H., et al. Phase I and pharmacokinetic study of dacomitinib (PF-00299804), an oral irreversible, small molecule inhibitor of human epidermal growth factor receptor-1, -2, and -4 tyrosine kinases, in Japanese patients with advanced solid tumors. Invest New Drugs 2012; 30: 2352-63.
16. Ramalingam SS, Blackhall F, Krzakowski M., et al. Randomized Phase II Study of Dacomitinib (PF-00299804), an Irreversible Pan-Human Epidermal Growth Factor Receptor Inhibitor, Versus Erlotinib in Patients With Advanced Non-Small-Cell Lung Cancer. J Clin Oncol 2012; 30: 3337-44.
17. Jänne P.A., Wang X, Socinski M.A., et al. Randomized phase II trial of erlotinib alone or with carboplatin and paclitaxel in patients who were never or light former smokers with advanced lung adenocarcinoma: CALGB 30406 trial J Clin Oncol 2012; 30: 2063-9.
18. Rosell R, Carcereny E, Gervais R., et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012; 13: 239-46.
19. Kobayashi T, Koizumi T, Agatsuma T., et al. A phase II trial of erlotinib in patients with EGFR wild-type advanced non-small-cell lung cancer. Cancer Chemother Pharmacol 2012; 69: 1241-6.
20. Gridelli C, Ciardiello F, Gallo C., et al. First-Line Erlotinib Followed by Second-Line Cisplatin-Gemcitabine Chemotherapy in Advanced Non-Small-Cell Lung Cancer: The TORCH Randomized Trial. J Clin Oncol 2012; 30: 3002-11.
21. Brugger W, Triller N, Blasinska-Morawiec M, et al. Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer. J Clin Oncol 2011; 29: 4113-20.
22. Spigel DR, Burris HA 3rd, Greco FA, et al. Randomized, double-blind, placebo-controlled, phase II trial of sorafenib and erlotinib or erlotinib alone in previously treated advanced non-small-cell lung cancer. J Clin Oncol 2011; 29: 2582-9.
23. Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2011; 12: 735-42.
24. Herbst RS, Ansari R, Bustin F., et al. Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial. Lancet 2011; 377: 1846-54.
25. Lilenbaum R, Axelrod R, Thomas S., et al. Randomized phase II trial of erlotinib or standard chemotherapy in patients with advanced non-small-cell lung cancer and a performance status of 2. J Clin Oncol 2008; 26: 863-9.
26. Felip E, Rojo F, Reck M., et al. A phase II pharmacodynamic study of erlotinib in patients with advanced non-small cell lung cancer previously treated with platinum-based chemotherapy. Clin Cancer Res 2008; 14: 3867-74.
27. Han W, Lo HW Landscape of EGFR signaling network in human cancers: biology and therapeutic response in relation to receptor subcellular locations. Cancer Lett 2012; 318: 124-34.
28. Wang YN, Hung MC Nuclear functions and subcellular trafficking mechanisms of the epidermal growth factor receptor family. Cell Biosci 2012; 2:13.
29. Wheeler DL, Dunn EF, Harari PM Understanding resistance to EGFR inhibitors-impact on future treatment strategies. Nat Rev Clin Oncol 2010; 7: 493-507.